Aragen and Innovent collaborate for biotherapeutics development

Privately-held US firm Aragen Bioscience and China-based Innovent Biologics have initiated a collaboration for the development of manufacturing cell lines for biotherapeutic product development. Under the terms of the agreement, Aragen Bioscience is developing robust CHO cell lines and assessing critical product quality attributes for various antibodies and protein therapeutics. Financial terms of the accord were not disclosed.

“Aragen Bioscience has demonstrated expertise in cell line development and protein product characterization. We recently completed the first technology transfer of the collaboration and are continuing with multiple additional products,” said Michael Yu, chief executive of Innovent.

As a contract research organization that offers a complete range of high-quality services, Aragen focuses on customer service and technical leadership to enable clients to cost-effectively accelerate their research efforts. Aragen offers cell line development, protein expression and purification, molecular biology, cell biology immunology and diverse in vivo services to the biotech and pharmaceutical industries.